MedTrace Logo

Individually Adapted Therapy of Alcoholism

NCT00317031 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 435

Last updated 2008-06-27

No results posted yet for this study

Summary

The primary objective is to directly compare the efficacy of acamprosate, naltrexone and placebo for relapse prevention in alcoholics.

Conditions

  • Alcoholism

Interventions

DRUG

Acamprosate or Naltrexone

mg\&d 90 days

Sponsors & Collaborators

  • German Federal Ministry of Education and Research

    collaborator OTHER_GOV

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Dupont Applied Biosciences

    collaborator INDUSTRY

  • Central Institute of Mental Health, Mannheim

    lead OTHER

Principal Investigators

  • Karl F. Mann, MD · Central Institute of Mental Health, J5, 68159 Mannheim, Germany

  • Michael N. Smolka, MD · Central Insitute of Mental Health, J5, 68159 Mannheim, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00317031 on ClinicalTrials.gov